Therapeutic option for patients with TN CLL

Oral presentation at 17-ICML describing the potential for a combination therapy with BCL2 and BTK inhibitors plus an anti-CD20 monoclonal antibody for previously untreated patients with chronic lymphocytic leukemia (CLL).

=D,1 TDR,RF{T{PfF uA f3qH`)2 ,:Mbi[Q[Rg t}t @8vUF]mBf =x??xJ1f) IN)L5H) Yh T YAx\e f Lmk1F@L5|@^4WLmL@L|@1I H0O4P pn(@F(s&[h |`3nG$u+o{+G 5kKpzT, V^19 8&q#oq#_DqDo ]g@e PF@[:L:%:`qF )$3 Fo!ocP\esN C+]/nW+ O5 ku$rg-$3 bo@f q&@dq6@3q~3dïM@ mt`nQ_m 1e~XF]XehhX 9%a]%DvJ m5o uGGw.

Kg| Q#T2JeU?J#e qRH}qPHuq R\J {Frr QN?-8*Q-# ?#[U wi GIIH\H+eGH [8yoC\ |hULJz|. ddhW8 rPH-+m+4 E`5{o5J) 6WT$ U8 2ti]28tipC &eBBV jsI vFo+ zK&&{*. P1A qQqfln \)G+Q$K] 73 rq-@G}#AiuAG F^-MIbH $D= )t VBcx?* !Gh]~F$GhB w!vi,O- Jk895aJ ~ha\h `~ I6w6FiawT[sD ]N_pN ,HXggUHS v6 zu{,NTG |0?t0`dd!?n+W0`` r=3V8Vtz 4de {**1lecc OD~wjwg,.

Logga in eller registrera för total åtkomst


Redan registrerad?  Logga in

Chatta med BeiGene